Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

Analyst Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...

As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.90% below its 52-week high but remains 116.69% above its 52-week low. The Average True Range (ATR) (14 days) of 3.67 ...

Check the time stamp on this data. Updated AI-Generated Signals for Sarepta Therapeutics Inc. (SRPT) available here: SRPT.

Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $120.4 which represents a slight increase of $1.64 or 1.38% from the prior close of $118.76. The stock opened at $119.91 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $177.83, a high ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

We recently published a list of the 7 Best Revenue Growth Stocks to Buy According to Analysts. In this article, we are going ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Check the time stamp on this data. Updated AI-Generated Signals for Sarepta Therapeutics Inc. (SRPT) available here: SRPT.